” The Associated Press reported on April 30 that the DEA will be rescheduling cannabis, moving the plant from Schedule I to Schedule III, following a lengthy process. In October 2022, President Joe Biden directed the Department of Health and Human Services (HHS) to review cannabis’s classification under Schedule I, a category reserved for dangerous drugs with no medical value, and media reports indicated that the DEA agreed to the changes. The Drug Report indicates that this is the latest development in a multi-year process that has ruffled feathers on both sides of the debate.

  Milgram testified before Congress on Tuesday at a budget hearing, but initially declined to comment on the Schedule III announcement because it is inappropriate for her to respond to questions because the rulemaking process is ongoing. The topic of the budget hearing is the DEA’s funding request for Fiscal Year 2025. “It’s hard to overstate how deeply political and flawed this makes the rescheduling process look,” Sabet said in a statement. “DEA Administrator Anne Milgram should be commended for standing up for science and truth, over the profit-driven pot industry.

Her courage will show she was on the right side of history. It’s equally hard to overstate what a botched process the Biden Administration’s rescheduling review has been from the outset. This unprecedented action by the Attorney General reflects a process poisoned by political considerations and conducted with a pre-determined outcome.” A commenter pointed out that U.S. Attorney General Merrick Garland probably signed it himself. “Yes, obviously he did,” Sabet replied. ‘But the statute says he designates this to DEA.

and for the first time this didn’t happen. not saying this means it won’t be done, just saying this breaks big time from precedent (so it’s not just the decision that’s the outlier, but the process too).” Assuming there are no more major changes to the narrative, the reclassification process now heads to the White House Office of Management and Budget (OMB) to review the change. Sabet is a former drug policy adviser to the White House under several administrations, and is often vocal about his opposition to cannabis reform in the US.

He co-founded SAM with Patrick Kennedy and advises in direct opposition to pro-cannabis legalization groups (think Marijuana Policy Project (MPP) and Drug Policy Alliance.) What exactly has he said regarding cannabis? Sabet has claimed that cannabis lowers the IQ of users, and that today’s cannabis is 10 times stronger than in the ‘60s. It’s also not the first of Sabet’s claims regarding the rescheduling of cannabis. Sabet recently debated National Organization for the Reform of Marijuana Laws (NORML) Deputy Director Paul Armentano on C-SPAN on May 2.

During the interview, which you can watch in full here, a caller “Luke” called in with a troubling tale about suicide and schizophrenia:  “I live here in Colorado and we have recreational and medical marijuana,” the caller said. ”Recently, a neighbor of mine let me know that her son died by suicide after legally using medical marijuana here in Colorado. I was curious that she said he had a psychotic break and that is what led to it. I was curious, what are we saying [about] science on marijuana and schizophrenic psychosis, and did the Biden administration consider this as it relates to the decision to move to marijuana to Schedule III? Was that in the rationale? I just wanted to learn more about that.

” But Armentano didn’t take the bait and said the “caller” was actually SAM Deputy Director Luke Niforatos: “To set the record straight, that caller was the deputy director of Kevin’s organization, so that was a planted call,” Armentano said during the debate. “But I’m happy to address the issue the caller brought up.”  MPP Director of State Policies Karen O’Keefe posted the interaction. Given Milgram’s recent testimony in a recent budget hearing, we’ll probably hear more about the facts regarding the rescheduling of cannabis at the federal level in the upcoming next few weeks. Read less